TITLE:
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

CONDITION:
Urologic Neoplasms

INTERVENTION:
ALIMTA

SUMMARY:

      Definition: Patients with bladder cancer will be participating in this study for the
      treatment of abnormal cells in the bladder that have returned after initial treatment OR
      have moved to a new site in the body.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  You must have been diagnosed with bladder cancer that has recurred or moved to a new
             part of the body.

          -  You must have at least one tumor that can be physically measured or scanned by x-ray.

          -  You may not have had previous chemotherapy (drug) treatment OR you have had surgery
             followed by one chemotherapy treatment at least 4 months ago.

        Exclusion Criteria:

          -  You may not have used an experimental medicine or device within the past month.

          -  Cancer that has spread to your brain.

          -  If you are unwilling or unable to take folic acid or vitamin B12 supplements.
      
